MA30988B1 - Composes destines a inhiber la progression mitotique - Google Patents

Composes destines a inhiber la progression mitotique

Info

Publication number
MA30988B1
MA30988B1 MA31985A MA31985A MA30988B1 MA 30988 B1 MA30988 B1 MA 30988B1 MA 31985 A MA31985 A MA 31985A MA 31985 A MA31985 A MA 31985A MA 30988 B1 MA30988 B1 MA 30988B1
Authority
MA
Morocco
Prior art keywords
compounds
mitotic progression
inhibiting mitotic
cancer
treatment
Prior art date
Application number
MA31985A
Other languages
English (en)
French (fr)
Inventor
Christopher F Claiborne
Todd B Sells
Stephen G Stroud
Original Assignee
Millennium Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39315133&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA30988(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Millennium Pharm Inc filed Critical Millennium Pharm Inc
Publication of MA30988B1 publication Critical patent/MA30988B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
MA31985A 2006-11-16 2009-06-12 Composes destines a inhiber la progression mitotique MA30988B1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US85934006P 2006-11-16 2006-11-16

Publications (1)

Publication Number Publication Date
MA30988B1 true MA30988B1 (fr) 2009-12-01

Family

ID=39315133

Family Applications (1)

Application Number Title Priority Date Filing Date
MA31985A MA30988B1 (fr) 2006-11-16 2009-06-12 Composes destines a inhiber la progression mitotique

Country Status (34)

Country Link
US (7) US8026246B2 (OSRAM)
EP (4) EP2497772B1 (OSRAM)
JP (3) JP5102839B2 (OSRAM)
KR (2) KR101110458B1 (OSRAM)
CN (2) CN101547924B (OSRAM)
AR (1) AR064246A1 (OSRAM)
AT (1) ATE556076T1 (OSRAM)
AU (1) AU2007322046B2 (OSRAM)
BR (1) BRPI0718803B8 (OSRAM)
CA (1) CA2669680C (OSRAM)
CL (1) CL2007003244A1 (OSRAM)
CR (3) CR10782A (OSRAM)
CY (1) CY1112828T1 (OSRAM)
DK (2) DK2086981T3 (OSRAM)
EA (1) EA015779B1 (OSRAM)
ES (3) ES2537451T3 (OSRAM)
GE (1) GEP20125459B (OSRAM)
HR (2) HRP20120490T1 (OSRAM)
IL (1) IL198690A0 (OSRAM)
MA (1) MA30988B1 (OSRAM)
MX (3) MX348568B (OSRAM)
MY (1) MY153243A (OSRAM)
NO (1) NO343338B1 (OSRAM)
NZ (3) NZ597252A (OSRAM)
PH (1) PH12012502057B1 (OSRAM)
PL (2) PL2497772T3 (OSRAM)
PT (2) PT2086981E (OSRAM)
RS (2) RS53788B1 (OSRAM)
SG (2) SG10201503350TA (OSRAM)
SI (2) SI2497772T1 (OSRAM)
TW (1) TWI401255B (OSRAM)
UA (1) UA94129C2 (OSRAM)
WO (1) WO2008063525A1 (OSRAM)
ZA (1) ZA200903279B (OSRAM)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2299080T3 (es) * 2004-05-14 2008-05-16 Millennium Pharmaceuticals, Inc. Compuestos y metodos para inhibir la progresion mitotica mediante la inhibicion de quinasas aurora.
CL2007003244A1 (es) * 2006-11-16 2008-04-04 Millennium Pharm Inc Compuestos derivados de pirimido[5,4-d][2]benzazepina; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento del cancer.
WO2010065134A1 (en) * 2008-12-05 2010-06-10 Millennium Pharmaceuticals, Inc. 5, 7-dihydro- 6h-pyrimido [ 5, 4-d] [ 1 ] benzazepin-6-thiones as plk inhibitors
WO2010074724A1 (en) * 2008-12-22 2010-07-01 Millennium Pharmaceuticals, Inc. Combination of aurora kinase inhibitors and anti-cd20 antibodies
JO3635B1 (ar) 2009-05-18 2020-08-27 Millennium Pharm Inc مركبات صيدلانية صلبة وطرق لانتاجها
JO3434B1 (ar) * 2009-07-31 2019-10-20 Millennium Pharm Inc مركبات صيدلانية لمعالجة السرطان وامراض واضطرابات اخري
US8653064B2 (en) 2010-02-19 2014-02-18 Millennium Pharmaceuticals, Inc. Crystalline forms of sodium 4-{[9-chloro-7-(2-fluoro-6-methoxyphenyl)-5H-pyrimido[5,4-D][2]benzazepin-2-yl]amino}-2-methoxybenzoate
US20120107304A1 (en) 2010-04-27 2012-05-03 Boehringer Ingelheim International Gmbh Combination therapy in treatment of oncological and fibrotic diseases
WO2011161031A1 (en) * 2010-06-22 2011-12-29 Glaxosmithkline Llc Benzotriazolodiazepine compounds inhibitors of bromodomains
UY34114A (es) 2011-06-03 2013-01-03 Millennium Pharm Inc Combinación de inhibidores de mek e inhibidores selectivos de la quiinasa aurora a
US20130303519A1 (en) 2012-03-20 2013-11-14 Millennium Pharmaceuticals, Inc. Methods of treating cancer using aurora kinase inhibitors
CN103772391A (zh) * 2012-10-23 2014-05-07 杨子娇 一类治疗房角狭窄的化合物及其用途
US9724354B2 (en) 2013-03-22 2017-08-08 Millennium Pharmaceuticals, Inc. Combination of catalytic mTORC1/2 inhibitors and selective inhibitors of Aurora A kinase
EP3076963A4 (en) 2013-12-06 2017-09-13 Millennium Pharmaceuticals, Inc. Combination of aurora kinase inhibitors and anti-cd30 antibodies
WO2016106357A1 (en) * 2014-12-23 2016-06-30 Millennnium Pharmaceuticals, Inc. Combination of raf inhibitors and aurora kinase inhibitors
JP2018524292A (ja) 2015-07-21 2018-08-30 ミレニアム ファーマシューティカルズ， インコーポレイテッドＭｉｌｌｅｎｎｉｕｍ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． オーロラキナーゼインヒビターと化学療法剤の投与
CA2997769A1 (en) 2015-09-09 2017-03-16 Icahn School Of Medicine At Mount Sinai Heterocyclic constrained tricyclic sulfonamides as anti-cancer agents
CN108349961B (zh) 2015-09-09 2022-02-18 西奈山伊坎医学院 杂环受限三环磺酰胺作为抗癌试剂
JP6591036B2 (ja) 2016-02-26 2019-10-16 公益財団法人がん研究会 Ｈｐ１の機能に着目した抗癌剤のスクリーニング方法及び評価系
SG11201807965YA (en) 2016-03-15 2018-10-30 Oryzon Genomics Sa Combinations of lsd1 inhibitors for use in the treatment of solid tumors
JP6188986B1 (ja) * 2017-03-23 2017-08-30 株式会社ノエビア 時計遺伝子発現量調整剤及びエラスチン産生促進剤
WO2019195658A1 (en) 2018-04-05 2019-10-10 Dana-Farber Cancer Institute, Inc. Sting levels as a biomarker for cancer immunotherapy
WO2020049208A1 (es) 2018-09-09 2020-03-12 Fundacio Privada Institut De Recerca De La Sida - Caixa Aurora cinasa como diana para tratar, prevenir o curar una infección por vih o sida
WO2021041532A1 (en) 2019-08-26 2021-03-04 Dana-Farber Cancer Institute, Inc. Use of heparin to promote type 1 interferon signaling
EP4504710A1 (en) 2022-04-07 2025-02-12 Eli Lilly and Company Process for making a kras g12c inhibitor
WO2023196887A1 (en) 2022-04-08 2023-10-12 Eli Lilly And Company Method of treatment including kras g12c inhibitors and aurora a inhibitors
US20240108618A1 (en) 2022-06-30 2024-04-04 Eli Lilly And Company Kras g12c inhibitor dosing regimens
WO2025075211A1 (en) 2023-10-03 2025-04-10 Takeda Pharmaceutical Company Limited Alisertib and paclitaxel for treating small cell lung cancer
WO2025245045A1 (en) 2024-05-21 2025-11-27 The Regents Of The University Of California Methods of treating lung cancer

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4099012A (en) * 1975-08-28 1978-07-04 Ciba-Geigy Corporation 2-pyrazolyl-benzophenones
FR2450833A1 (fr) 1979-02-07 1980-10-03 Hoffmann La Roche Derives de benzazepine
US4481142A (en) * 1979-02-07 1984-11-06 Hoffmann-La Roche Inc. Pyrimido-2-benzazepines
US4469633A (en) * 1980-05-16 1984-09-04 Hoffmann-La Roche Inc. N-oxides of 5-oxo-1-phenyl-2-benzazepines
EP0273697A3 (en) 1986-12-30 1989-11-29 Merck & Co. Inc. 2-benzazepines with 5- and 6- membered heterocyclic rings
US5166151A (en) * 1988-03-25 1992-11-24 Merck & Co., Inc. 2-Benzazepines with 5- and 6-membered heterocyclic rings, compositions and medical methods of use thereof
US5210082A (en) * 1991-05-16 1993-05-11 Merck & Co., Inc. 2-benzazepines with 5- and 6-membered heterocyclic rings to treat pain and anxiety disorders
GB9523675D0 (en) 1995-11-20 1996-01-24 Celltech Therapeutics Ltd Chemical compounds
CN1084747C (zh) * 1996-03-08 2002-05-15 曾尼卡有限公司 作为神经活性剂的吡咯并苯并氮杂䓬衍生物
JP2001507349A (ja) * 1996-12-23 2001-06-05 セルテック セラピューティックス リミテッド 縮合多環式２−アミノピリミジン誘導体、それらの製造およびたんぱく質チロシンキナーゼ抑制因子としてのそれらの使用
GB9713087D0 (en) 1997-06-20 1997-08-27 Celltech Therapeutics Ltd Chemical compounds
CN1155599C (zh) * 1997-09-29 2004-06-30 明治制果株式会社 三环三唑并苯并氮杂�衍生物、用于制备该衍生物的方法和抗变态反应剂
US6277844B1 (en) * 1998-09-14 2001-08-21 Sydney Spector Compound for selective treatment of malignant cells by inhibiting cell cycle progression, decreasing Bcl2, and increasing apoptosis
US6417207B1 (en) 1999-05-12 2002-07-09 Nitromed, Inc. Nitrosated and nitrosylated potassium channel activators, compositions and methods of use
WO2001042199A1 (en) 1999-12-06 2001-06-14 Ajinomoto Co.,Inc. Amidinophenylpyruvic acid derivative
HUP0400639A3 (en) 2000-12-21 2010-03-29 Vertex Pharma Pyrazole compounds useful as protein kinase inhibitors and pharmaceutical compositions containing them
US6686352B2 (en) 2001-05-18 2004-02-03 Hoffmann-La Roche Inc. Substituted imidazo [1,5-a] pyrimido [5,4-d] [1] benzazepine derivatives
DE10135457A1 (de) * 2001-07-20 2003-02-06 Adc Automotive Dist Control Optische Sensoranordnung
BR0211729A (pt) 2001-08-09 2004-08-24 Actelion Pharmaceuticals Ltd Compostos, composições farmacêuticas, processo para fabricar compostos, uso de um ou mais compostos, e, processo para fabricar composições farmacêuticas
CN1897950A (zh) 2003-10-14 2007-01-17 惠氏公司 稠合芳基和杂芳基衍生物及其使用方法
ES2299080T3 (es) * 2004-05-14 2008-05-16 Millennium Pharmaceuticals, Inc. Compuestos y metodos para inhibir la progresion mitotica mediante la inhibicion de quinasas aurora.
WO2006055831A2 (en) 2004-11-17 2006-05-26 Miikana Therapeutics, Inc. Kinase inhibitors
US20100160324A1 (en) 2004-12-30 2010-06-24 Astex Therapeutics Limited Pyrazole derivatives as that modulate the activity of cdk, gsk and aurora kinases
SI1962830T1 (sl) 2005-12-23 2013-07-31 Glaxosmithkline Llc Azaindolni inhibitorji kinaz Aurora
EP2054413A2 (en) 2006-08-09 2009-05-06 Millennium Pharmaceuticals, Inc. Pyridobenzazepine compounds and methods for inhibiting mitotic progression
CL2007003244A1 (es) 2006-11-16 2008-04-04 Millennium Pharm Inc Compuestos derivados de pirimido[5,4-d][2]benzazepina; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento del cancer.
JO3635B1 (ar) 2009-05-18 2020-08-27 Millennium Pharm Inc مركبات صيدلانية صلبة وطرق لانتاجها

Also Published As

Publication number Publication date
EA015779B1 (ru) 2011-12-30
CL2007003244A1 (es) 2008-04-04
EP2086981A1 (en) 2009-08-12
EP2497772B1 (en) 2014-10-29
CR10782A (es) 2009-06-24
HK1217699A1 (en) 2017-01-20
EP2497773A1 (en) 2012-09-12
JP5452811B2 (ja) 2014-03-26
CR20140154A (es) 2014-07-23
CN101547924B (zh) 2013-09-25
US11958855B2 (en) 2024-04-16
US20110312942A1 (en) 2011-12-22
HRP20150047T1 (en) 2015-03-13
US8026246B2 (en) 2011-09-27
HK1175778A1 (en) 2013-07-12
MX2009004670A (es) 2009-05-15
PT2086981E (pt) 2012-06-20
US9988384B2 (en) 2018-06-05
RS53788B1 (sr) 2015-06-30
CN101547924A (zh) 2009-09-30
SI2497772T1 (sl) 2015-03-31
EP2497773B1 (en) 2015-02-25
NZ597252A (en) 2013-06-28
HK1175777A1 (en) 2013-07-12
KR101342014B1 (ko) 2013-12-19
AU2007322046B2 (en) 2012-04-05
CN103483343A (zh) 2014-01-01
JP5102839B2 (ja) 2012-12-19
HRP20120490T1 (hr) 2012-07-31
NO20091864L (no) 2009-06-15
TW200829589A (en) 2008-07-16
PT2497772E (pt) 2015-02-05
CA2669680A1 (en) 2008-05-29
US10836766B2 (en) 2020-11-17
CY1112828T1 (el) 2016-02-10
CA2669680C (en) 2012-04-10
AU2007322046A1 (en) 2008-05-29
TWI401255B (zh) 2013-07-11
EP2944639A1 (en) 2015-11-18
KR101110458B1 (ko) 2012-03-13
GEP20125459B (en) 2012-03-26
PH12012502057B1 (en) 2018-10-24
RS52313B (sr) 2012-12-31
US20110312943A1 (en) 2011-12-22
ES2528793T3 (es) 2015-02-12
US20150166545A1 (en) 2015-06-18
KR20090091173A (ko) 2009-08-26
NZ611898A (en) 2015-01-30
JP2012006965A (ja) 2012-01-12
BRPI0718803A2 (pt) 2013-12-03
PL2086981T3 (pl) 2012-09-28
DK2497772T3 (en) 2015-01-19
DK2086981T3 (da) 2012-08-06
US20080167292A1 (en) 2008-07-10
US20240400567A1 (en) 2024-12-05
IL198690A0 (en) 2010-02-17
UA94129C2 (ru) 2011-04-11
HK1134672A1 (en) 2010-05-07
SG176443A1 (en) 2011-12-29
CR20140544A (es) 2015-01-12
CN103483343B (zh) 2016-06-01
SG10201503350TA (en) 2015-06-29
ES2537451T3 (es) 2015-06-08
EA200970486A1 (ru) 2009-10-30
EP2086981B1 (en) 2012-05-02
MX348568B (es) 2017-06-20
MX343391B (es) 2016-11-04
US9765076B2 (en) 2017-09-19
KR20110113210A (ko) 2011-10-14
NZ577042A (en) 2012-03-30
US20210214361A1 (en) 2021-07-15
ATE556076T1 (de) 2012-05-15
MY153243A (en) 2015-01-29
NO343338B1 (no) 2019-02-04
EP2497772A1 (en) 2012-09-12
JP2010510215A (ja) 2010-04-02
BRPI0718803B1 (pt) 2020-11-17
ES2384123T3 (es) 2012-06-29
BRPI0718803B8 (pt) 2021-05-25
AR064246A1 (es) 2009-03-25
PL2497772T3 (pl) 2015-05-29
WO2008063525A1 (en) 2008-05-29
US20190031662A1 (en) 2019-01-31
ZA200903279B (en) 2010-07-28
PH12012502057A1 (en) 2015-09-14
SI2086981T1 (sl) 2012-12-31
JP2014055166A (ja) 2014-03-27
EP2944639B1 (en) 2017-01-04

Similar Documents

Publication Publication Date Title
MA30988B1 (fr) Composes destines a inhiber la progression mitotique
TNSN07305A1 (fr) Agonistes de pyy et leurs utilisations
MA31574B1 (fr) Dérivés de pyrazole et leur utilisation comme inhibiteurs de raf
MA30166B1 (fr) Imidazoles substitues et leur utilisation comme pesticides.
MA30781B1 (fr) Inhibiteur de kinase
MA31906B1 (fr) Inhibiteurs de la replication du virus de limmunodeficience humaine
MA33275B1 (fr) Inhibiteurs de la replication du virus de l'immunodeficience humaine
MA29688B1 (fr) Formulation d'un inhibiteur de l'agregation plaquettaire thienopyridine
TN2011000454A1 (fr) Derives de benzofurannyle utilises comme inhibiteurs de glucokinase
WO2019035863A8 (en) PYRUVATE KINASE ACTIVATORS FOR USE IN THE TREATMENT OF HEMATOLOGICAL DISORDERS
MA32104B1 (fr) Dérivés d'oxime en tant qu'inhibiteurs de hsp90
MA32135B1 (fr) Inhibiteurs de pim kinase et leurs procedes d'utilisation
MA40225B1 (fr) Composés dihydroisoquinolinone substitués
MA34361B1 (fr) Dérivés de tétrahydro-pyrido-pyrimidine
MA31433B1 (fr) Inhibiteurs de la p70 s6 kinase
MA29160B1 (fr) Derives de triazole substitues, servant d'antagonistes d'ocytocine
WO2006123113A3 (en) Pyrazolylaminopyrimidine derivatives useful as tyrosine kinase inhibitors
MA32468B1 (fr) Derives de thiophene ou de thiazole et leur utilisation comme inhibiteurs de pi3k
MA32904B1 (fr) Composes de purine
MA31741B1 (fr) Derives fongicides de 2-alkylthio-2-quinolinyloxy- acetamide
MA33730B1 (fr) Procédés de synthèse pour des composés spiro-oxindoles
TNSN08444A1 (en) Bicyclic derivatives as cetp inhibitors
MY149512A (en) Pyrazolylaminopyridine derivatives useful as kinase inhibitors
MA30351B1 (fr) Composes de tetrahydropyridothienopyrimidine et leurs procedes d'utilisation
MA37798B1 (fr) 4-méthyl-2,3,5,9,9b-pentaaza-cyclopenta[a]naphtalènes